Allarity Therapeutics (NASDAQ:ALLR) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.18), FiscalAI reports. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Allarity Therapeutics updated its FY 2026 guidance to -0.760–0.730 EPS and its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Trading Up 3.7%

Shares of NASDAQ:ALLR opened at $0.87 on Thursday. Allarity Therapeutics has a twelve month low of $0.77 and a twelve month high of $1.84. The company has a market cap of $13.95 million, a PE ratio of -0.89 and a beta of 0.57. The company’s 50 day moving average is $0.99 and its 200 day moving average is $1.20.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Allarity Therapeutics has a consensus rating of “Hold” and a consensus price target of $10.25.

Check Out Our Latest Research Report on Allarity Therapeutics

Allarity Therapeutics Company Profile

(Get Free Report)

Allarity Therapeutics is a biotechnology company focused on developing precision-medicine treatments for cancer. Its approach combines oncology drug development with tools intended to help identify patients who may be more likely to respond to a particular therapy. The company’s Drug Response Predictor (DRP) technology analyzes gene-expression data to estimate how a patient’s tumor may respond to a drug. Allarity has developed the platform for use in selecting patients for clinical studies and as a potential companion diagnostic.

Featured Stories

Earnings History for Allarity Therapeutics (NASDAQ:ALLR)

Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.